CGT

24개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved24 programs
CGTLimited DatastaleAllife Medical Science and Tech…Phase 1

CRISPR/Cas9 (CRISPR/Cas9)

Human Papillomavirus-Related Malignant Neoplasm · Human Papillomavirus-Related Malignant N

#HumanPapillomavirus-RelatedMalig#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 50Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 30Status Recruiting
CGTCurated CorestaleREGENXBIO Inc.Phase 2

RGX-314 (RGX-314)

Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#BioJungboMoa-pick#cell-gene-therapy+4
Trials 12Status Active
CGTLimited DatastaleFrontera TherapeuticsPhase 2

FT-003 (FT-003)

Diabetic Macular Edema · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 (AAV2-hAQP1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 1 (AAV2-hAQP1 Concentration 1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 2 (AAV2-hAQP1 Concentration 2)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 3 (AAV2-hAQP1 Concentration 3)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 4 (AAV2-hAQP1 Concentration 4)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleGenzyme, a Sanofi CompanyPhase 1

AAV2-sFLT01 (AAV2-sFLT01)

Macular Degeneration; Age-Related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleCelosia Therapeutics Pty LtdPhase 1

AAV9 Gene therapy (AAV9 Gene therapy)

ALS (Amyotrophic Lateral Sclerosis) · ALS (Amyotrophic Lateral Sclerosis)

#ALSAmyotrophicLateralSclerosis#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTAAVLimited DatastaleUnlimited Biotechnology LLCPhase 2

AAV9-Follistatin gene therapy (AAV9-Follistatin gene therapy)

Age-related Muscle Decline · Age-related Muscle Decline

#Age-relatedMuscleDecline#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleAkouos, Inc.Phase 2

AAVAnc80-hOTOF via Akouos Delivery Device (AAVAnc80-hOTOF via Akouos Delivery Device)

Sensorineural Hearing Loss, Bilateral · Sensorineural Hearing Loss, Bilateral

#SensorineuralHearingLossBilatera#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAkouos, Inc.Phase 2

AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism (AAVAnc80-hOTOF via Akouos Delivery Device and Precision Delivery Mechanism)

Sensorineural Hearing Loss, Bilateral · Sensorineural Hearing Loss, Bilateral

#SensorineuralHearingLossBilatera#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJanssen Research & Development,…Phase 1

AAVCAGsCD59 (AAVCAGsCD59)

Dry Age-related Macular Degeneration · Dry Age-related Macular Degeneration

#DryAge-relatedMacularDegeneratio#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 2

AAVrh.10CUCLN2 (AAVrh.10CUCLN2)

Late Infantile Neuronal Ceroid Lipofuscinosis; Batten Disease · Late Infantile Neuronal Ceroid Lipofusci

#LateInfantileNeuronalCeroidLipof#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleNeurologix, Inc.Phase 2

Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)

Parkinson's Disease · Parkinson's Disease

#ParkinsonsDisease#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleChanghai HospitalPhase 1

CD19/BCMA CAR NK (CD19/BCMA CAR NK)

IgG4 Related Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →